SuperworthEdwards Lifesciences EPS EW
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $1.74
- Latest quarter, Q2 FY26
- $0.42
- −25% on a year earlier
- Fiscal year 2025
- $1.83
- −74% on the year before
Edwards Lifesciences' earnings per share was $1.74 over the twelve months to Jun 30, 2026, down 75% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.42, down 25% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 7% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.83 | −74% |
| FY2024 | $6.97 | +203% |
| FY2023 | $2.30 | −6% |
| FY2022 | $2.44 | +2% |
| FY2021 | $2.39 | +84% |
| FY2020 | $1.30 | −21% |
| FY2019 | $1.64 | +46% |
| FY2018 | $1.12 | +25% |
| FY2017 | $0.90 | +3% |
| FY2016 | $0.87 | +16% |
| FY2015 | $0.75 | −40% |
| FY2014 | $1.25 | +121% |
| FY2013 | $0.57 | +38% |
| FY2012 | $0.41 | +25% |
| FY2011 | $0.33 | +8% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.42 | −25% | $1.74 | |
| Q1 FY26 | $0.66 | +8% | $1.88 | |
| Q4 FY25 | $0.16 | −75% | $1.83 | |
| Q3 FY25 | $0.50 | −90% | $2.32 | |
| Q2 FY25 | $0.56 | −8% | $6.95 | |
| Q1 FY25 | $0.61 | +5% | $7.00 | |
| Q4 FY24 | $0.65 | +7% | $6.97 | |
| Q3 FY24 | $5.13 | +714% | $6.93 | |
| Q2 FY24 | $0.61 | +22% | $2.43 | |
| Q1 FY24 | $0.58 | +4% | $2.32 | |
| Q4 FY23 | $0.61 | −6% | $2.30 | |
| Q3 FY23 | $0.63 | +15% | $2.34 |
Against its peers
Companies in Medical - Devices nearest Edwards Lifesciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EWEdwards Lifesciences | $1.74 | −75% a year |
| BSXBoston Scientific | $2.47 | +47% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| DXCMDexCom | $2.52 | +76% a year |
| SYKStryker | $9.65 | +28% a year |
| MDTMedtronic | $4.07 | +12% a year |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| ABTAbbott Laboratories | $2.68 | −66% a year |
| Peer median | $4.07 |
Where Edwards Lifesciences ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Edwards Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.